10-KPeriod: FY2006

STRYKER CORP Annual Report, Year Ended Dec 31, 2006

Filed February 28, 2007For Securities:SYK

Summary

Stryker Corporation's 2006 10-K filing reveals a robust year of growth and strategic acquisitions, positioning the company as a leader in medical technology. The company reported net sales of $5.41 billion, an 11% increase year-over-year, driven by strong performance in both its Orthopaedic Implants and MedSurg Equipment segments. Significant product launches and the successful integration of recent acquisitions, including Sightline Technologies, PlasmaSol, and eTrauma, contributed to this growth. Financially, Stryker demonstrated solid profitability, with net earnings of $777.7 million, a 21% increase from the previous year. The company's investment in research and development (R&D) increased to 6.0% of sales, reflecting a commitment to innovation and future product pipelines, particularly in advanced implant technologies and surgical equipment. The company maintained a strong balance sheet with substantial cash and marketable securities, providing ample resources for ongoing operations, potential future acquisitions, and shareholder returns.

Key Highlights

  • 1Stryker reported net sales of $5.41 billion in 2006, an 11% increase over 2005, driven by strong performance in both Orthopaedic Implants and MedSurg Equipment segments.
  • 2Net earnings reached $777.7 million, a 21% increase from 2005, indicating healthy profitability.
  • 3The company increased its R&D spending to 6.0% of net sales, highlighting a focus on innovation and new product development.
  • 4Strategic acquisitions, including Sightline Technologies, PlasmaSol, and eTrauma, were completed to enhance product offerings and market presence.
  • 5The company maintained a strong liquidity position with $1.41 billion in cash and marketable securities at year-end 2006.
  • 6Sales in the Orthopaedic Implants segment grew by 9%, with notable strength in Spine and Craniomaxillofacial implant systems.
  • 7MedSurg Equipment segment sales increased by 16%, driven by robust growth in Surgical Equipment, Digital Imaging Systems, and Patient Handling Equipment.

Frequently Asked Questions

Stryker's growth in 2006 was driven by a combination of factors including strong unit volume increases across its Orthopaedic Implants and MedSurg Equipment segments, successful new product introductions and line extensions, and the integration of strategic acquisitions. Specifically, the Spine and Craniomaxillofacial implant systems, as well as Surgical Equipment, Digital Imaging Systems, and Patient Handling Equipment, showed particularly strong performance.

Stryker increased its R&D spending to 6.0% of net sales in 2006. This increased investment reflects the company's strategic focus on developing proprietary products and enhancing existing lines to maintain its competitive edge and drive future sales growth, particularly in areas like advanced implant technologies and innovative surgical and imaging systems.

Stryker completed several strategic acquisitions, including Sightline Technologies, PlasmaSol, and eTrauma. These acquisitions were aimed at expanding its product portfolio, particularly in flexible endoscopes and sterilization equipment for the MedSurg segment. The company incurred significant charges for purchased in-process research and development related to these acquisitions, which impacted reported net earnings, but expects them to contribute to future sales and market presence.

The filing identifies several key risks, including the potential negative impact of stricter pricing guidelines and healthcare cost-containment initiatives in the orthopaedic industry, the risk of product obsolescence due to rapid market changes, the company's reliance on healthcare professionals for product development and sales, and potential negative impacts from future product liability claims or unfavorable court decisions. Additionally, regulatory delays in product approvals and economic or political instability in international markets are noted as risks.